Pulmonary Mortality after High-Dose Oral Busulfan and Autologous Stem Cell Transplant (ASCT) in Patients with Non-Hodgkin Lymphoma (NHL)
| Autor: | Lisa Rybicki, Brian J. Bolwell, Ronald Sobecks, Elizabeth Kuczkowski, Stacey Brown, Steven Andresen, Matt Kalaycio, Brad Pohlman |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
medicine.medical_specialty
Chemotherapy Lung Cyclophosphamide Pulmonary toxicity business.industry medicine.medical_treatment Immunology Cell Biology Hematology Biochemistry Gastroenterology Pulmonary function testing Surgery medicine.anatomical_structure DLCO Internal medicine medicine business Busulfan Cause of death medicine.drug |
| Zdroj: | Blood. 106:1764-1764 |
| ISSN: | 1528-0020 0006-4971 |
| Popis: | Many high-dose chemotherapy preparative regimens include agents known to cause pulmonary toxicity such as BCNU. Chemotherapy induced pulmonary toxicity may be fatal. From 1/1/93 to 12/31/04 we treated 533 NHL patients with oral busulfan 14mg/kg, VP-16 60 mg/kg, and cyclophosphamide 120 mg/kg followed by ASCT. Busulfan levels were not measured. We have followed these patients for toxicity, survival, and cause of death (COD). Of these 533 patients, 214 have died, and 53 have died without relapse (15%). Most patients (n=329; 62%) had intermediate grade NHL by the IWF system. The median age was 50 years (range, 16–77) and 43% had a history of smoking. Radiotherapy was delivered to 27% and less than 3 chemotherapy regimens were administered to 75% of patients before ASCT. Sixteen patients (3%) died of non-relapse pulmonary complications. The median time to pulmonary mortality was 5 months (range, 2.5 – 21.4 months). We routinely screen patients with pulmonary function tests including DLCO before ASCT and most patients (n=490; 92%) were screened at a median of 45 days after ASCT (range, 7–90 days). For patients for whom data was available, there was no significant decrease in the median pre-ASCT and the post-ASCT DLCO in the either the whole cohort of patients or the patients dying of pulmonary complications. However, a lower baseline DLCO before ASCT predicted for pulmonary mortality after ASCT in univariable and multivariable analysis. Patients with a baseline DLCO |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|